Menstrual blood-derived mesenchymal stem cells (MenSCs)

Cell therapy

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Featured evidence outside this drug's tracked markets:NCT01496339 · Type 1 Diabetes Mellitus · Phase 1/2 · Weak signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (2)
Other / comorbidity
NCT01483248 · S-Evans Biosciences Co., Ltd.
2010-10 – 2015-10 · Liver Cirrhosis, Fibrosis, Liver Disease, Digestive System Disease
What this study did
NCT01496339 · S-Evans Biosciences Co., Ltd.
2012-01 – 2014-05 · Type 1 Diabetes Mellitus
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.